Inventor
CHANG RONG-KUN
US26 patents
⚠️ This page may combine multiple inventors who share the name “CHANG RONG-KUN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SHIRE LAB INC
8 patentsUS6913768B2Jul 5, 2005
Sustained release delivery of amphetamine salts
SHIRE LAB INC266 citations98
US6605300B1Aug 12, 2003
Oral pulsed dose drug delivery system
SHIRE LAB INC118 citations98
US6287599B1Sep 11, 2001
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SHIRE LAB INC216 citations98
US6811794B2Nov 2, 2004
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SHIRE LAB INC105 citations97
US6322819B1Nov 27, 2001
Oral pulsed dose drug delivery system
SHIRE LAB INC348 citations97
US6384020B1May 7, 2002
Rapid immediate release oral dosage form
SHIRE LAB INC131 citations95
US6890918B2May 10, 2005
Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers
SHIRE LAB INC38 citations90
US6793934B1Sep 21, 2004
Solid oral dosage form
SHIRE LAB INC27 citations89
CHANG RONG-KUN
8 patentsUS8906413B2Dec 9, 2014
Drug formulations having reduced abuse potential
CHANG RONG-KUN24 citations92
US8470364B2Jun 25, 2013
Once daily formulations of tetracyclines
CHANG RONG-KUN9 citations92
US8748472B2Jun 10, 2014
Stabilized formulations of CNS compounds
CHANG RONG-KUN11 citations83
US8394405B2Mar 12, 2013
Once daily formulations of tetracyclines
CHANG RONG-KUN6 citations83
US8394406B2Mar 12, 2013
Once daily formulations of tetracyclines
CHANG RONG-KUN6 citations83
US8206740B2Jun 26, 2012
Once daily formulations of tetracyclines
CHANG RONG-KUN7 citations83
US9308176B2Apr 12, 2016
Less abusable pharmaceutical preparations
CHANG RONG-KUN2 citations62
US8808714B2Aug 19, 2014
Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
CHANG RONG-KUN1 citations51
SUPERNUS PHARMACEUTICALS INC
6 patentsUS7910128B2Mar 22, 2011
Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
SUPERNUS PHARMACEUTICALS INC40 citations92
US7749532B2Jul 6, 2010
Once daily formulations of tetracyclines
SUPERNUS PHARMACEUTICALS INC10 citations92
US8709478B2Apr 29, 2014
Once daily formulations of tetracyclines
SUPERNUS PHARMACEUTICALS INC5 citations84
US11077114B2Aug 3, 2021
Stabilized formulations of CNS compounds
SUPERNUS PHARMACEUTICALS INC1 citations72
US10149853B2Dec 11, 2018
Stabilized formulations of CNS compounds
SUPERNUS PHARMACEUTICALS INC2 citations72
US9144551B2Sep 29, 2015
Drug formulations having reduced abuse potential
SUPERNUS PHARMACEUTICALS INC1 citations52